Cost-Effectiveness Analysis of Ceftazidime-Avibactam and Meropenem in the Treatment of Complex Abdominal Infection in Adults

目的：开展头孢他啶–阿维巴坦与美罗培南治疗成人复杂腹腔感染的成本–效果分析，为医疗决策者提供参考。方法：基于Ⅲ期临床试验(NCT01726023)的研究数据及中国的医疗成本，采用TreeAge Pro 2011软件构建决策树模型，并对评价结果进行敏感性分析。结果：头孢他啶–阿维巴坦组的期望成本为26925.52元，成本–效果比为10199.06；美罗培南组的期望成本为6438.38元，成本–效果比为2402.38；增量成本–效果比为−512,175。敏感性分析结果显示模型稳定。结论：虽然头孢他啶–阿维巴坦治疗成人复杂腹腔感染疗效不劣于美罗培南，但在我国目前的经济形势下，头孢他啶–阿维巴坦暂不具有成本–效果优势。Objective: To carry out the cost-effectiveness analysis of Ceftazidime-avibactam and meropenem in the treatment of complex abdominal infection in adults, so as to provide reference for medical decision-makers. Methods: Based on the data of phase III clinical trial (NCT01726023) and medical costs in China, a decision tree model was constructed by TreeAge Pro 2011 software, and the sensitivity of the evaluation results was analyzed. Results: The expected costs and cost-effectiveness ratio of Ceftazidime-avibactam group were 26925.52 yuan and 10199.06 respectively; The expected costs and cost-effectiveness ratio of meropenem group were 6438.38 yuan and 2402.38 respectively. And the cost-effectiveness ratio for efficiency improvement is −512,175. Sensitivity analysis shows that the model is stable. Conclusion: Although the efficacy of Ceftazidime-avibactam in the treatment of complex abdominal infection in adults is not inferior to meropenem, ceftazidime-avertam does not have a cost-effectiveness advantage in the current economic situation in China.